64319-85-3

Basic information

• Product Name: 3-broMo-5-(3,4-dihydro-2H-pyrrol-5-yl)pyridine
• Synonyms: 3-broMo-5-(3,4-dihydro-2H-pyrrol-5-yl)pyridine
• CAS NO: 64319-85-3
• Molecular Formula: C₉H₉BrN₂
• Molecular Weight: 225.08516
• Mol File: 64319-85-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-broMo-5-(3,4-dihydro-2H-pyrrol-5-yl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-broMo-5-(3,4-dihydro-2H-pyrrol-5-yl)pyridine(64319-85-3)
• EPA Substance Registry System: 3-broMo-5-(3,4-dihydro-2H-pyrrol-5-yl)pyridine(64319-85-3)

Safety Data

• Hazardous Substances Data: 64319-85-3(Hazardous Substances Data)

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 47, p. 4165, 1982 DOI: 10.1021/jo00142a032

Upstream product

• 88-12-0 1-ethenyl-2-pyrrolidinone 
• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 
• 201292-62-8 3-(5-Bromo-pyridine-3-carbonyl)-1-vinyl-pyrrolidin-2-one 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 

Downstream Products

• 71719-06-7 5-Bromo-3-(2-pyrrolidinyl)pyridine 
• 5746-86-1 rac-nornicotine 
• 350820-80-3 rac-2-(3-pyridinyl)-1-pyrrolidinebutanoic acid phenylmethyl ester 
• 179120-51-5 SIB-1765F 
• 71719-09-0 5-bromo-3-(1-methyl-2-pyrrolidinyl)pyridine 
• 179120-92-4 altinicline 
• 83023-58-9 (S)-5-bromo-3-(1H-2-pyrrolidinyl)pyridine 
• 83023-56-7 3-bromo-5-(pyrrolidin-2-yl)pyridine 
• 494-97-3 nornicotine 
• 7076-23-5 (+)-nornicotine 

Relevant articles and documents

Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo

Since the demonstration of nicotine vaccines as a possible therapeutic intervention for the effects of tobacco smoke, extensive effort has been made to enhance nicotine specific immunity. Linker modifications of nicotine haptens have been a focal point for improving the immunogenicity of nicotine, in which the evaluation of these modifications usually relies on in vivo animal models, such as mice, rats or nonhuman primates. Here, we present two in vitro screening strategies to estimate and predict the immunogenic potential of our newly designed nicotine haptens. One utilizes a competition enzyme-linked immunoabsorbent assay (ELISA) to profile the interactions of nicotine haptens or hapten-protein conjugates with nicotine specific antibodies, both polyclonal and monoclonal. Another relies on computational modeling of the interactions between haptens and amino acid residues near the conjugation site of the carrier protein to infer linker-carrier protein conjugation effect on antinicotine antibody response. Using these two in vitro methods, we ranked the haptens with different linkers for their potential as viable vaccine candidates. The ELISA-based hapten ranking was in an agreement with the results obtained by in vivo nicotine pharmacokinetic analysis. A correlation was found between the average binding affinity (IC50) of the haptens to an anti-Nic monoclonal antibody and the average brain nicotine concentration in the immunized mice. The computational modeling of hapten and carrier protein interactions helps exclude conjugates with strong linker-carrier conjugation effects and low in vivo efficacy. The simplicity of these in vitro screening strategies should facilitate the selection and development of more effective nicotine conjugate vaccines. In addition, these data highlight a previously under-appreciated contribution of linkers and hapten-protein conjugations to conjugate vaccine immunogenicity by virtue of their inclusion in the epitope that binds and activates B cells.

NOVEL NICOTINE DNA VACCINES

The present invention provides DNA-nanostructures comprising and at least one targeting moiety, wherein the at least one targeting moiety is linked to the DNA-nanostructure; and wherein the at least one targeting moiety is nicotine or a nicotine analogue. These compounds elicit an immunogenic response in individuals and are useful as vaccines for ameliorating nicotine dependence.

An immunotherapeutic program for the treatment of nicotine addiction: Hapten design and synthesis

People continue to smoke and use tobacco products despite well-established hazardous consequences. The most contributing factor is the addictive nature of nicotine. There is no highly effective treatment for the problem of nicotine dependence. Immunotherapy offers an alternative to conventional approaches. The chemistry necessary for a comprehensive immunopharmacological program is presented. Haptens for the generation of antibodies specific for naturally occurring (S)-nicotine, (S)- and (R)-nornicotine, and the metabolite (S)-cotinine were prepared with high optical purity. Preliminary data for antinicotine antibodies are reported.